HENGRUI PHARMA Shares Surge on Major Strategic Alliance with Bristol-Myers Squibb, Deal Valued Up to $15.2 Billion

Stock News05-12

HENGRUI PHARMA (01276) experienced a sharp increase in afternoon trading, rising over 16% at its peak. As of the latest update, the stock was up 6.21%, trading at HKD 70.15 with a turnover of HKD 1.014 billion.

The surge follows an announcement from HENGRUI PHARMA that it has entered into a global strategic collaboration and licensing agreement with Bristol-Myers Squibb (BMS). The partnership will focus on advancing 13 early-stage projects in oncology, hematology, and immunology.

Under the terms of the agreement, BMS will make payments to HENGRUI PHARMA totaling up to $950 million. This includes an upfront payment of $600 million, a first anniversary payment of $175 million, and a conditional second anniversary payment of $175 million in 2028.

The total potential value of the agreement could reach approximately $15.2 billion. This figure accounts for the exercise of options for joint research and development projects, as well as the achievement of development, registration, and commercialization milestones across all projects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment